Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study — Valerie J. Ludbrook (2016) | RDL Network
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
Article 2016 en
Authors
VL
Valerie J. Ludbrook
KH
Kirsty Hicks
KH
Kate Hanrott
Abstract
1 min read
Our study demonstrates that 12 weeks of treatment with GSK2586184 resulted in clinical improvement and was generally well tolerated in patients with moderate-to-severe plaque-type psoriasis.
Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths
Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Phyllis I. Spuls, Christopher Em Griffiths, Alexander Nast, J Franke, C. Antoniou, Petr Arenberger, Flora Balieva, Matilda Bylaitė, Osvaldo Correia, E. Daudén, Paolo Gisondi, Lars Iversen, Lajos Kemény, M. Lahfa, Tamar Nijsten, Tapio Rantanen, Adam Reich, T. Rosenbach, Siegfried Segaert, Catherine Smith, T. Talme,
Hans Skvara, Markus Dawid, Elise Kleyn, Barbara Wolff, Josef G. Meingassner, Hilary Knight, Thomas Dumortier, Tamara Kopp, Nasanin Fallahi, Georg Stary, Christoph Burkhart, Olivier Grenet, Juergen Wagner, Youssef Hijazi, Randall E. Morris, Claire McGeown, Christiane Rordorf, Christopher Em Griffiths, Georg Stingl, Thomas Jung
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.